相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Does In Vitro Potency Predict Clinically Efficacious Concentrations?
Rasmus Jansson-Lofmark et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018
Jose R. Franco et al.
PLOS NEGLECTED TROPICAL DISEASES (2020)
Chiral Chromatographic Isolation on Milligram Scale of the Human African Trypanosomiasis Treatment D- and L-Eflornithine
Mikael Boberg et al.
ACS OMEGA (2020)
Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay
Annabelle Walz et al.
MALARIA JOURNAL (2019)
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial
Victor Kande Betu Ku Mesu et al.
LANCET (2018)
Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents
Eduardo Asin-Prieto et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2015)
Enantiospecific Reassessment of the Pharmacokinetics and Pharmacodynamics of Oral Eflornithine against Late-Stage Trypanosoma brucei gambiense Sleeping Sickness
R. Jansson-Lofmark et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Trypanosoma brucei eflornithine transporter AAT6 is a low-affinity low-selective transporter for neutral amino acids
Christoph Mathieu et al.
BIOCHEMICAL JOURNAL (2014)
Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
Nicholas J. White
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat
Carl-Christer Johansson et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2013)
Untargeted Metabolomics Reveals a Lack Of Synergy between Nifurtimox and Eflornithine against Trypanosoma brucei
Isabel M. Vincent et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Isolation of Trypanosoma brucei gambiense from Cured and Relapsed Sleeping Sickness Patients and Adaptation to Laboratory Mice
Patient Pati Pyana et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Inhibitory Activity of Marine Sponge-Derived Natural Products against Parasitic Protozoa
Ilkay Orhan et al.
MARINE DRUGS (2010)
A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes
Isabel M. Vincent et al.
PLOS PATHOGENS (2010)
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial
Gerardo Priotto et al.
LANCET (2009)
Enantioselective and nonlinear intestinal absorption of eflornithine in the rat
R. Jansson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Nifurtimox-Eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness:: A randomized clinical trial in Congo
Gerardo Priotto et al.
CLINICAL INFECTIOUS DISEASES (2007)
Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate
Naomi Maina et al.
ACTA TROPICA (2007)
Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series
Francesco Checchi et al.
PLOS NEGLECTED TROPICAL DISEASES (2007)
The pharmacokinetics of eflornithine (α-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness
K Na-Bangchang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine
N Qu et al.
BIOCHEMICAL JOURNAL (2003)
Eflornithine for the treatment of human African trypanosomiasis
C Burri et al.
PARASITOLOGY RESEARCH (2003)
分享论文
